ELN Validation: Part 11 & GxP Guide

Choosing an electronic lab notebook (ELN) and validating one for regulated use are different projects with different failure modes. A lab picking software cares about usability, integrations, and cost. A lab operating under Good Laboratory Practice (GLP), Good Clinical Practice (GCP), or Good Manufacturing Practice (GMP), collectively GxP, has a further, non-negotiable obligation: demonstrating, with documented evidence, that the system does what it’s supposed to do, reliably, and that its electronic records and signatures meet 21 CFR Part 11. This guide covers that second project: what Part 11 and GxP actually require of an ELN, how the validation lifecycle works in practice, and where responsibility splits between the vendor and the institution. It assumes you’ve already selected an ELN platform; for the selection process itself, see Lab Notebook Software: How to Choose an Electronic Lab Notebook and, for what a compliant record actually looks like day to day, Electronic Lab Notebook Template: Fields, Structure & Audit Trail.

Does your lab actually need Part 11 validation?

Not every lab using an ELN is subject to Part 11. The regulation applies to electronic records and signatures that FDA requires under a predicate rule, a specific existing FDA regulation, such as GLP (21 CFR Part 58), GCP-related recordkeeping, or GMP (21 CFR Part 211), requiring the record to be kept or submitted in the first place. FDA’s 2003 guidance, Part 11, Electronic Records; Electronic Signatures — Scope and Application, narrowed the practical scope of Part 11 to records that meet both conditions: a predicate rule requires the record, and the record is maintained electronically in place of paper. An academic lab with no predicate-rule obligation, most basic-research work, is not automatically in Part 11’s scope merely because it uses electronic records. The trigger is regulatory intent: is this data destined to support an IND/NDA/BLA submission, a GLP nonclinical safety study, GCP clinical trial source data, or GMP batch records? If yes, validation is mandatory, not optional. If a lab’s status is ambiguous (for example, contract research supporting an eventual regulatory filing, or academic work that may later feed an industry partnership), the safer default is to validate as though it will be needed, since retrofitting validation onto years of unvalidated records after the fact is far more expensive than building it in from the start.

What 21 CFR Part 11 requires of an ELN

Part 11 has three subparts. Subpart A sets general provisions and definitions. Subpart B (Sections 11.10–11.70) governs electronic records; Section 11.10, “Controls for closed systems,” is the operative checklist and applies almost item-for-item to an ELN:

11.10(a) — Validation. The system must be validated to ensure accuracy, reliability, and the ability to detect invalid or altered records.
11.10(b)/(c) — Record generation and protection. The system must be able to generate accurate, complete copies of records (including in human-readable and electronic form for inspection) and protect records so they remain readily retrievable throughout the required retention period.
11.10(d) — Access limitation. Only authorized individuals can access or modify the system, enforced through role-based permissions.
11.10(e) — Audit trails. A secure, computer-generated, time-stamped audit trail must independently record the date, time, and identity of the operator for every create, modify, and delete action, and that trail must be retained for at least as long as the underlying record and available for review and copying.
11.10(f)/(g) — Operational and authority checks. The system enforces the correct sequence of steps and events, and confirms that only authorized individuals can use the system, sign a record, or perform an operation.
11.10(h) — Device checks. Where applicable, checks confirm the validity of the data source or input device.
11.10(i)/(j) — Personnel and accountability. Personnel developing, maintaining, or using the system have appropriate education, training, and experience, and there are written policies holding individuals accountable for actions taken under their electronic signatures.
11.10(k) — Documentation controls. Controls over system and operational documentation, including revision and change control, are in place.

Subpart C (Sections 11.100–11.300) covers electronic signatures. Section 11.50 requires a signed record to display the signer’s printed name, the date and time of signing, and the meaning associated with the signature (review, approval, responsibility, or authorship). Section 11.70 requires signatures to be linked to their records so they can’t be excised, copied, or transferred to falsify a record. Sections 11.100–11.300 govern signature uniqueness (no two individuals share a signature; a signature isn’t reused or reassigned), identity verification before an organization certifies a signature to FDA, and controls for both biometric and non-biometric signatures, including the two-component (ID plus password, or equivalent) requirement for non-biometric signatures used in a session.

Part 11 is the electronic-records-and-signatures layer; it does not replace the underlying predicate rule (GLP/GCP/GMP), which continues to set what must be recorded and retained in the first place. See the full definitions and structure at 21 CFR Part 11: Electronic Records & Signatures, and for the specific GxP frameworks: Good Laboratory Practice (GLP), Good Clinical Practice (GCP), and Good Manufacturing Practice (GMP).

No ELN is “Part 11 compliant” out of the box

Vendors market ELN products as “Part 11-ready” or “GxP-capable,” and that framing is accurate as far as it goes: it means the software has the technical capability to support compliant use, audit trails, e-signature workflows, role-based access, and so on. It does not mean the deployment is validated. Part 11’s Section 11.10(a) validation requirement, and the predicate rule’s broader quality-system expectations, attach to the specific, configured, operating instance of the system at your institution, not to the vendor’s generic product. A vendor can and typically does provide a substantial part of the evidence base, but final responsibility for demonstrating that the deployed system performs as intended, in your environment, with your configuration, procedures, and personnel, sits with the regulated entity, not the software vendor. This split matters practically: a vendor’s Installation Qualification (IQ) protocol assumes a specific, controlled installation process, and if your IT team deviates from it (different server environment, different SSO integration, different backup cadence), the vendor’s validation package no longer covers what you actually run.

The computer system validation (CSV) lifecycle for an ELN

Validating an ELN follows the same general computer system validation (CSV) lifecycle used across GxP software, typically organized around a risk-based framework such as ISPE’s GAMP 5 (Good Automated Manufacturing Practice; second edition published 2022). The core stages:

User Requirements Specification (URS). Document what the ELN must do for your specific regulated use: which studies or record types it will hold, which signature workflows are required (author, reviewer, witness/co-signer), retention periods, and integration points (LIMS, instruments, ERP).
Risk assessment and GAMP category. GAMP 5 categorizes software by configurability and risk (from infrastructure software up through configured and custom applications) to scale validation effort to actual risk rather than applying one exhaustive test script to every feature regardless of impact. A configurable commercial ELN typically falls into GAMP’s “configured products” category, meaning validation focuses on the configuration and workflows you’ve built, not on re-testing the vendor’s core code.
Installation Qualification (IQ). Documented evidence that the system was installed correctly, in the intended environment, per specification, this is site-specific even when a vendor supplies an IQ protocol template.
Operational Qualification (OQ). Testing that the system’s functions, audit trail capture, e-signature workflow, access controls, template locking, calculation functions, operate correctly across the range of expected conditions, including negative testing (confirming unauthorized actions are correctly blocked).
Performance Qualification (PQ) / User Acceptance Testing (UAT). Testing the system performing its intended use, by its intended users, against real or representative workflows, confirming it works as needed for actual regulated work, not just in the abstract.
Validation summary report and release. A signed document summarizing the validation evidence, any deviations and their resolution, and a formal statement that the system is fit for its intended, regulated use.
Maintaining the validated state. Validation is not a one-time event. Change control governs any configuration change, template edit, or vendor-issued update; periodic review confirms the system remains fit for purpose; and re-validation (scoped to the affected functionality, not necessarily a full re-run) is triggered by significant changes, including vendor platform upgrades on cloud/SaaS ELNs that the institution doesn’t control the timing of.

FDA’s finalized guidance Computer Software Assurance for Production and Quality System Software (issued September 2025, targeted at production and quality system software under the Quality System Regulation) formalizes a risk-based “critical thinking” approach that scales assurance effort to risk rather than defaulting to exhaustive scripted testing for every feature. GAMP 5’s second edition was developed in parallel and explicitly aligns with this philosophy. The practical implication for ELN validation: rigorous testing should concentrate on GxP-critical functions, audit trail integrity, e-signature meaning and binding, access control enforcement, calculation accuracy, rather than spreading equal test depth across every low-risk configuration option.

Data integrity and audit trail: the parts inspectors actually check

In FDA and other regulatory inspections, ELN data integrity findings concentrate disproportionately on a small set of issues. Building validation and ongoing operating procedures around these reduces the most common finding categories:

ALCOA+ compliance. Records must be Attributable, Legible, Contemporaneous, Original, and Accurate, plus Complete, Consistent, Enduring, and Available. An ELN’s audit trail and metadata are what make these properties demonstrable after the fact; see ALCOA+ (Clinical Trial Data Integrity Principles) for the full framework.
Audit trail review, not just capture. Capturing an audit trail satisfies 11.10(e) technically, but inspectors increasingly expect evidence that audit trails are actually reviewed on a defined schedule (for example, alongside data review before batch release or study lock), with a documented Standard Operating Procedure describing who reviews what, how often, and how discrepancies are escalated. See Standard Operating Procedure (SOP).
Signature meaning and binding. Confirm the ELN’s e-signature workflow correctly attaches printed name, timestamp, and stated meaning (11.50) and that a completed signature can’t be detached or reused (11.70). Test this explicitly in OQ, not just assume the vendor handles it.
Role-based access and shared credentials. Shared logins are one of the most common findings across GxP software audits generally; the ELN’s access control must map to individually attributable accounts, and validation should include negative tests confirming a user can’t perform actions outside their assigned role.
Long-term readability. Section 11.10(b) requires records to remain accessible and copyable throughout the retention period, which for GLP/GCP/GMP records commonly runs to years or decades. Validate the institution’s plan for reading records if the ELN vendor is discontinued, acquired, or the platform is migrated, not just that today’s export function works.

Cloud/SaaS ELNs: what changes and what doesn’t

Most current commercial ELNs are cloud/SaaS-hosted rather than on-premises. This shifts, but doesn’t remove, validation responsibility. The institution can typically rely on the vendor’s SOC 2 Type II report or equivalent third-party audit evidence to support infrastructure- and security-layer assurance (physical security, network controls, backup and disaster recovery) rather than independently re-testing that layer. What the institution still owns: validating its own configuration, workflows, and integrations; confirming the vendor’s change-management process gives adequate advance notice of platform updates so the institution can assess impact before an update lands (an update the institution doesn’t control the timing of is still a validation-affecting change once it’s deployed); and maintaining a documented vendor qualification file, covering the vendor’s own quality system, audit history, and the specific SLA/data-processing terms governing your instance. A Data Processing Agreement or Quality Agreement with the vendor, defining responsibilities for each side of this split, is standard practice and worth having in place before validation begins, not after an inspection asks for it.

Practical validation checklist

URS written and approved before configuration begins, tied to the specific predicate rule(s) in scope
GAMP risk category assigned and validation effort scoped proportionally
IQ documenting the actual installed/configured environment, not a generic vendor template alone
OQ testing audit trail capture, e-signature meaning/binding, role-based access (including negative tests), calculation functions, and template locking/version control
PQ/UAT run by actual end users against representative regulated workflows
Validation summary report signed and retained per your quality system’s document control requirements
Change control procedure covering configuration changes, template revisions, and vendor-issued platform updates
Periodic review schedule and audit trail review SOP in place, not just a validation event at go-live
Personnel training records demonstrating 11.10(i) qualification for anyone administering, configuring, or using the system for regulated records
Documented plan for record accessibility if the vendor relationship or platform changes before the retention period ends
Vendor qualification file: SOC 2 or equivalent audit evidence, Quality/Data Processing Agreement, escalation and change-notification terms

Frequently asked questions

Is a “Part 11-compliant” ELN the same as a validated ELN?

No. “Part 11-compliant” (or “GxP-capable”) describes the software’s technical capability to support compliant use. Validation is the documented evidence that your specific, configured instance actually performs as intended for its regulated purpose. A capable product that’s never been validated at your site is not a compliant deployment.

Does every lab using an ELN need to validate it under Part 11?

Only if a predicate rule (GLP, GCP-related recordkeeping, GMP, or another FDA regulation) requires the records the ELN holds. Basic academic research with no regulatory submission in view generally falls outside Part 11’s practical scope under FDA’s 2003 scope-and-application guidance, though institutions doing contract or translational work that may later feed a regulatory filing often validate proactively rather than retrofit records after the fact.

How often does a validated ELN need to be revalidated?

There’s no fixed universal interval; it’s driven by change and periodic review, not a calendar alone. A significant configuration change, template revision affecting GxP-critical fields, or a vendor platform update that touches validated functionality should trigger a scoped revalidation of the affected area. Most quality systems also require a periodic review (commonly annual) to confirm the system remains fit for purpose even absent a specific triggering change.

Can a cloud/SaaS ELN be fully validated, or does GxP require on-premises hosting?

Cloud/SaaS ELNs can be validated, and most current commercial ELN deployments in regulated labs are cloud-hosted. Validation responsibility shifts (the institution typically relies on vendor SOC 2/audit evidence for infrastructure controls rather than re-testing them) but doesn’t disappear; the institution still owns configuration validation, change control for vendor-driven updates, and vendor qualification.

What’s the difference between FDA’s Computer Software Assurance (CSA) approach and traditional computer system validation?

CSA, formalized in FDA’s guidance finalized in September 2025 for production and quality system software, is a risk-based philosophy that scales testing rigor and documentation effort to a feature’s actual risk, favoring critical thinking and unscripted testing for low-risk functions over exhaustive scripted test cases applied uniformly. It doesn’t replace Part 11’s underlying requirements (validation, audit trails, access controls still apply); it changes how much documented testing effort is proportionate to demonstrate them. GAMP 5’s second edition (2022) was developed to align with this same risk-based direction.

Electronic Lab Notebook Validation Under 21 CFR Part 11 and GxP